You are here

Application of CDX-MDM in Pre-Clinical Model of Murine Pulmonary Emphysema

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41HL115965-01A1
Agency Tracking Number: R41HL115965
Amount: $99,674.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NHLBI
Solicitation Number: PA12-089
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
United States
DUNS: 965175958
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (202) 687-5341
Business Contact
Phone: (434) 409-1881
Research Institution
United States

 () -
 Nonprofit College or University

DESCRIPTION (provided by applicant): The objective of this proposal is to exploit a newly discovered anti-inflammatory function involving the aminopeptidase activity of the leukotriene A4 hydrolase for the treatment of pulmonary emphysema. The leukotrieneA4 hydrolase is a dual-functioning enzyme with dichotomously opposing functions. As an epoxide hydrolase, it catalyzes the conversion of leukotriene A4 to leukotriene B4 in pro-inflammatory processes. As an aminopeptidase, it catalyzes the digestion of thetripeptide sequences like Pro-Gly-Pro in anti-inflammatory processes. For the first time, we have created a pharmacological agent (4-MDM) with which the aminopeptidase activity of the leukotriene A4 hydrolase can be selectively up-regulated. We hypothesized that the treatment with 4-MDM will protect lungs from developing pulmonary emphysema. Preliminary results demonstrated that the 4-MDM treatment effectively protected murine lungs from emphysema induced by intra- nasal elastase. Subsequently, we formulated 4-MDM to be stably water soluble as a potential oral agent (CDX- MDM). Enhanced water solubility of the CDX-MDM has enabled us to administer this agent in a chronic animal model of pulmonary emphysema. Building upon this preliminary work, we propose toconduct the efficacy study of the CDX-MDM in a murine model of pulmonary emphysema induced by cigarettes smoke which resembles human disease most closely. Emphysema develops over a long duration of trigger (cigarette smoke) exposure. Therefore, developinga biomarker assay which measures the pharmaceutical effects of the drug could also be a desirable tool to overcome the long duration of onset during the development of a pharmaceutical agent. We developed a biomarker assay which the aminopeptidase activityof the leukotriene A4 hydrolase can be measured in plasma ex vivo. In this grant application, we also propose to test this assay with the plasma samples from the animals treated with the CDX-MDM or placebo. In combination, this project will provide necessary evidence on which the CDX-MDM will be developed as a potential therapy for emphysema. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Pulmonary emphysema is an irreversible lung disease of increasing prevalence for which effective disease modifying therapy is not available. Based on these needs, we propose specific aims with a novel compound to develop a medical therapy for pulmonary emphysema. We believe that our project will lead to new therapeutic options for patients who suffer from pulmonary emphysema.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government